Nalini Bora
Concepts (240)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uveitis, Anterior | 10 | 2019 | 28 | 3.450 |
Why?
| Autoimmune Diseases | 11 | 2019 | 114 | 3.370 |
Why?
| Choroidal Neovascularization | 17 | 2022 | 65 | 3.310 |
Why?
| Complement System Proteins | 7 | 2014 | 55 | 2.030 |
Why?
| Macular Degeneration | 10 | 2016 | 49 | 2.010 |
Why?
| Disease Models, Animal | 22 | 2022 | 1639 | 1.800 |
Why?
| Autoantigens | 5 | 2009 | 64 | 1.330 |
Why?
| Complement Activation | 8 | 2010 | 43 | 1.320 |
Why?
| Uveitis | 5 | 2009 | 28 | 1.130 |
Why?
| Rats, Inbred Lew | 13 | 2019 | 67 | 1.130 |
Why?
| Immune Tolerance | 6 | 2009 | 104 | 1.100 |
Why?
| Transforming Growth Factor beta2 | 5 | 2019 | 17 | 0.910 |
Why?
| Animals | 41 | 2022 | 14385 | 0.910 |
Why?
| Rats | 16 | 2019 | 3415 | 0.780 |
Why?
| Choroid | 5 | 2012 | 26 | 0.740 |
Why?
| Geographic Atrophy | 2 | 2016 | 9 | 0.690 |
Why?
| Complement Factor B | 2 | 2011 | 9 | 0.690 |
Why?
| Complement Pathway, Alternative | 2 | 2011 | 11 | 0.680 |
Why?
| Antigens, Surface | 3 | 2010 | 55 | 0.680 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2009 | 85 | 0.670 |
Why?
| Eye Diseases | 3 | 2008 | 35 | 0.670 |
Why?
| Recombinant Proteins | 4 | 2019 | 569 | 0.630 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2011 | 180 | 0.620 |
Why?
| Adiponectin | 6 | 2022 | 76 | 0.620 |
Why?
| Complement Membrane Attack Complex | 6 | 2011 | 21 | 0.600 |
Why?
| Eye | 4 | 2006 | 36 | 0.600 |
Why?
| Collagen Type I | 2 | 2009 | 97 | 0.570 |
Why?
| Antigens, Neoplasm | 2 | 2008 | 170 | 0.520 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2014 | 673 | 0.500 |
Why?
| Neovascularization, Pathologic | 3 | 2012 | 168 | 0.500 |
Why?
| Ethanol | 3 | 2008 | 322 | 0.500 |
Why?
| Lasers | 8 | 2011 | 141 | 0.490 |
Why?
| Blotting, Western | 6 | 2016 | 683 | 0.470 |
Why?
| Complement C4 | 2 | 2011 | 8 | 0.470 |
Why?
| Interleukin-2 Receptor alpha Subunit | 2 | 2009 | 12 | 0.450 |
Why?
| Receptors, Cell Surface | 2 | 2010 | 130 | 0.430 |
Why?
| Male | 25 | 2020 | 27334 | 0.410 |
Why?
| Mice | 16 | 2022 | 6413 | 0.410 |
Why?
| Honey | 1 | 2011 | 8 | 0.410 |
Why?
| Keratitis | 1 | 2011 | 17 | 0.410 |
Why?
| Adoptive Transfer | 5 | 2011 | 38 | 0.400 |
Why?
| Pseudomonas Infections | 1 | 2011 | 54 | 0.400 |
Why?
| Eye Injuries | 1 | 2011 | 29 | 0.400 |
Why?
| Eye Infections, Bacterial | 1 | 2011 | 35 | 0.400 |
Why?
| Wound Healing | 2 | 2016 | 228 | 0.390 |
Why?
| Vascular Endothelial Growth Factor A | 8 | 2016 | 230 | 0.390 |
Why?
| Complement Factor H | 2 | 2010 | 10 | 0.390 |
Why?
| Complement C3 | 4 | 2014 | 31 | 0.380 |
Why?
| Down-Regulation | 3 | 2007 | 388 | 0.380 |
Why?
| Mice, Inbred C57BL | 11 | 2020 | 1999 | 0.380 |
Why?
| Protein Processing, Post-Translational | 2 | 2009 | 183 | 0.380 |
Why?
| Models, Biological | 1 | 2014 | 823 | 0.380 |
Why?
| Cell Proliferation | 6 | 2020 | 1096 | 0.370 |
Why?
| Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 314 | 0.370 |
Why?
| Apoptosis | 5 | 2014 | 1300 | 0.350 |
Why?
| Mice, Knockout | 5 | 2016 | 926 | 0.350 |
Why?
| Epitopes | 1 | 2009 | 89 | 0.350 |
Why?
| Complement Inactivator Proteins | 2 | 2006 | 5 | 0.350 |
Why?
| Immunohistochemistry | 5 | 2014 | 1089 | 0.320 |
Why?
| Wet Macular Degeneration | 2 | 2022 | 15 | 0.320 |
Why?
| Cattle | 4 | 2009 | 224 | 0.320 |
Why?
| Acyltransferases | 2 | 2006 | 27 | 0.310 |
Why?
| Complement C3b | 2 | 2006 | 8 | 0.300 |
Why?
| Retinal Pigment Epithelium | 3 | 2016 | 24 | 0.290 |
Why?
| Esters | 1 | 2006 | 25 | 0.280 |
Why?
| Immunity, Innate | 1 | 2007 | 114 | 0.270 |
Why?
| Lipoxygenase Inhibitors | 1 | 2005 | 6 | 0.260 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 26 | 0.260 |
Why?
| Angiogenesis Inhibitors | 2 | 2020 | 203 | 0.260 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2005 | 44 | 0.260 |
Why?
| Fatty Acids | 1 | 2006 | 174 | 0.260 |
Why?
| Nitric Oxide Synthase | 1 | 2005 | 102 | 0.260 |
Why?
| Antigens, CD | 2 | 2003 | 242 | 0.250 |
Why?
| Immunologic Factors | 1 | 2006 | 130 | 0.250 |
Why?
| Carboxylic Ester Hydrolases | 1 | 2003 | 6 | 0.240 |
Why?
| Injections, Intravenous | 3 | 2009 | 148 | 0.240 |
Why?
| Mutagenesis, Site-Directed | 1 | 2003 | 117 | 0.240 |
Why?
| Avian Proteins | 1 | 2003 | 6 | 0.230 |
Why?
| Antigen-Presenting Cells | 1 | 2003 | 25 | 0.230 |
Why?
| Blood Proteins | 1 | 2003 | 100 | 0.220 |
Why?
| Polyethylene Glycols | 2 | 2014 | 106 | 0.210 |
Why?
| Injections, Intraocular | 2 | 2019 | 7 | 0.210 |
Why?
| Cytokines | 3 | 2011 | 676 | 0.200 |
Why?
| Trabeculectomy | 1 | 2020 | 10 | 0.190 |
Why?
| Myocardium | 1 | 2003 | 441 | 0.190 |
Why?
| Trityl Compounds | 1 | 2020 | 3 | 0.190 |
Why?
| Butyric Acid | 1 | 2020 | 10 | 0.190 |
Why?
| Acetamides | 1 | 2020 | 25 | 0.190 |
Why?
| Transforming Growth Factor beta | 3 | 2006 | 158 | 0.180 |
Why?
| Peptide Fragments | 2 | 2012 | 242 | 0.180 |
Why?
| Endotoxins | 2 | 2011 | 37 | 0.180 |
Why?
| Glaucoma | 1 | 2020 | 64 | 0.170 |
Why?
| Specific Pathogen-Free Organisms | 2 | 2009 | 15 | 0.170 |
Why?
| Melanins | 2 | 2011 | 30 | 0.170 |
Why?
| Nicotine | 2 | 2012 | 207 | 0.170 |
Why?
| Immunoglobulin G | 2 | 2011 | 226 | 0.160 |
Why?
| Thalidomide | 1 | 2020 | 397 | 0.160 |
Why?
| RNA, Small Interfering | 3 | 2010 | 252 | 0.160 |
Why?
| Pigment Epithelium of Eye | 2 | 2010 | 15 | 0.150 |
Why?
| Lymph Nodes | 2 | 2009 | 284 | 0.150 |
Why?
| Humans | 16 | 2022 | 54284 | 0.140 |
Why?
| Gene Expression Regulation | 3 | 2014 | 1062 | 0.140 |
Why?
| T-Lymphocytes | 1 | 2019 | 373 | 0.140 |
Why?
| Retinal Degeneration | 1 | 2016 | 16 | 0.140 |
Why?
| Chemokine CCL2 | 2 | 2016 | 78 | 0.130 |
Why?
| Alcohol Drinking | 2 | 2008 | 259 | 0.130 |
Why?
| RNA, Messenger | 3 | 2010 | 1202 | 0.130 |
Why?
| Photoreceptor Cells, Vertebrate | 1 | 2014 | 4 | 0.130 |
Why?
| Amino Acid Sequence | 3 | 2009 | 767 | 0.130 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 142 | 0.130 |
Why?
| Aspirin | 1 | 2016 | 127 | 0.130 |
Why?
| Peptides | 2 | 2022 | 276 | 0.120 |
Why?
| Follow-Up Studies | 2 | 2011 | 2387 | 0.110 |
Why?
| In Situ Nick-End Labeling | 2 | 2014 | 64 | 0.110 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2012 | 16 | 0.110 |
Why?
| Molecular Sequence Data | 2 | 2004 | 980 | 0.110 |
Why?
| Receptors, Adiponectin | 3 | 2022 | 14 | 0.100 |
Why?
| Membrane Glycoproteins | 2 | 2003 | 269 | 0.100 |
Why?
| Proliferating Cell Nuclear Antigen | 3 | 2022 | 82 | 0.100 |
Why?
| Administration, Topical | 1 | 2011 | 71 | 0.100 |
Why?
| Cornea | 1 | 2011 | 62 | 0.100 |
Why?
| Pseudomonas aeruginosa | 1 | 2011 | 86 | 0.100 |
Why?
| Lipoproteins, LDL | 1 | 2012 | 195 | 0.100 |
Why?
| Drug Carriers | 1 | 2011 | 81 | 0.090 |
Why?
| Endothelium, Vascular | 1 | 2012 | 288 | 0.090 |
Why?
| Fluorescent Antibody Technique | 1 | 2010 | 141 | 0.090 |
Why?
| RNA | 1 | 2011 | 202 | 0.090 |
Why?
| Autoantibodies | 1 | 2011 | 132 | 0.090 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 240 | 0.090 |
Why?
| Lymphocyte Depletion | 1 | 2009 | 12 | 0.090 |
Why?
| Microscopy, Confocal | 3 | 2005 | 110 | 0.090 |
Why?
| Immunization | 1 | 2009 | 95 | 0.090 |
Why?
| Cell Membrane | 1 | 2010 | 278 | 0.090 |
Why?
| Lymphocyte Count | 1 | 2008 | 23 | 0.080 |
Why?
| Forkhead Transcription Factors | 1 | 2009 | 118 | 0.080 |
Why?
| Interleukin-2 | 1 | 2008 | 75 | 0.080 |
Why?
| Coculture Techniques | 1 | 2008 | 160 | 0.080 |
Why?
| Caspase 8 | 1 | 2007 | 16 | 0.080 |
Why?
| Caspase 9 | 1 | 2007 | 20 | 0.080 |
Why?
| Cytochromes c | 1 | 2007 | 41 | 0.080 |
Why?
| bcl-2-Associated X Protein | 1 | 2007 | 73 | 0.080 |
Why?
| Diet | 2 | 2016 | 598 | 0.080 |
Why?
| Cell Line | 3 | 2020 | 1153 | 0.080 |
Why?
| Caspase 3 | 1 | 2007 | 135 | 0.080 |
Why?
| Growth Substances | 1 | 2007 | 32 | 0.080 |
Why?
| Treatment Outcome | 2 | 2011 | 5604 | 0.080 |
Why?
| Anterior Chamber | 1 | 2007 | 10 | 0.070 |
Why?
| Complement C5 | 1 | 2006 | 3 | 0.070 |
Why?
| Complement C3-C5 Convertases | 1 | 2006 | 3 | 0.070 |
Why?
| Oligodeoxyribonucleotides, Antisense | 1 | 2006 | 4 | 0.070 |
Why?
| Receptors, Complement | 1 | 2006 | 4 | 0.070 |
Why?
| Complement C1q | 1 | 2006 | 11 | 0.070 |
Why?
| Antibodies, Blocking | 1 | 2006 | 8 | 0.070 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 158 | 0.070 |
Why?
| Cyclin E | 1 | 2006 | 6 | 0.070 |
Why?
| Macrophage-1 Antigen | 1 | 2006 | 8 | 0.070 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 122 | 0.070 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 26 | 0.070 |
Why?
| Cyclin-Dependent Kinase 2 | 1 | 2006 | 28 | 0.070 |
Why?
| Recombinant Fusion Proteins | 1 | 2007 | 206 | 0.070 |
Why?
| Cell Adhesion Molecules | 1 | 2006 | 87 | 0.070 |
Why?
| Inflammation | 1 | 2010 | 674 | 0.070 |
Why?
| Chemokines | 1 | 2006 | 96 | 0.070 |
Why?
| Models, Molecular | 1 | 2007 | 423 | 0.070 |
Why?
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 4 | 0.070 |
Why?
| Collagen | 1 | 2007 | 223 | 0.070 |
Why?
| Risk Factors | 1 | 2014 | 3935 | 0.070 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 20 | 0.070 |
Why?
| Cyclooxygenase 2 | 1 | 2005 | 49 | 0.070 |
Why?
| Injections, Subcutaneous | 1 | 2005 | 58 | 0.070 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2005 | 83 | 0.060 |
Why?
| Guanidines | 1 | 2005 | 36 | 0.060 |
Why?
| Immune Sera | 1 | 2004 | 24 | 0.060 |
Why?
| Flow Cytometry | 1 | 2007 | 546 | 0.060 |
Why?
| Macrophages | 1 | 2007 | 405 | 0.060 |
Why?
| Fibroblast Growth Factors | 1 | 2005 | 59 | 0.060 |
Why?
| Up-Regulation | 1 | 2006 | 508 | 0.060 |
Why?
| Pyrazoles | 1 | 2005 | 110 | 0.060 |
Why?
| Sequence Homology | 1 | 2003 | 21 | 0.060 |
Why?
| COS Cells | 1 | 2003 | 78 | 0.060 |
Why?
| Organ Specificity | 1 | 2004 | 126 | 0.060 |
Why?
| Bruch Membrane | 1 | 2003 | 1 | 0.060 |
Why?
| Sulfonamides | 1 | 2005 | 146 | 0.060 |
Why?
| Hypersensitivity, Delayed | 1 | 2003 | 21 | 0.060 |
Why?
| Enzyme Activation | 1 | 2003 | 329 | 0.060 |
Why?
| Fluorescein-5-isothiocyanate | 1 | 2022 | 11 | 0.060 |
Why?
| Interleukin-12 | 1 | 2003 | 37 | 0.060 |
Why?
| Disease Progression | 1 | 2006 | 913 | 0.060 |
Why?
| Ophthalmic Solutions | 1 | 2022 | 27 | 0.050 |
Why?
| Structure-Activity Relationship | 1 | 2003 | 423 | 0.050 |
Why?
| Interleukin-10 | 1 | 2003 | 107 | 0.050 |
Why?
| Antibodies, Neutralizing | 2 | 2012 | 75 | 0.050 |
Why?
| Cells, Cultured | 3 | 2012 | 1737 | 0.050 |
Why?
| Antibodies, Monoclonal | 1 | 2006 | 562 | 0.050 |
Why?
| Tetrazolium Salts | 1 | 2020 | 17 | 0.050 |
Why?
| Time Factors | 3 | 2014 | 3213 | 0.050 |
Why?
| Rats, Inbred BN | 2 | 2012 | 21 | 0.050 |
Why?
| Mitomycin | 1 | 2020 | 23 | 0.050 |
Why?
| Immunotherapy | 1 | 2003 | 263 | 0.050 |
Why?
| Lidocaine | 1 | 2020 | 48 | 0.050 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 95 | 0.050 |
Why?
| Aging | 1 | 2004 | 784 | 0.040 |
Why?
| Endothelial Cells | 2 | 2012 | 294 | 0.040 |
Why?
| Immunoenzyme Techniques | 2 | 2010 | 165 | 0.040 |
Why?
| Mutation | 1 | 2003 | 1501 | 0.040 |
Why?
| Female | 1 | 2016 | 28441 | 0.030 |
Why?
| Complement C1 Inhibitor Protein | 1 | 2014 | 5 | 0.030 |
Why?
| Aminopeptidases | 1 | 2014 | 18 | 0.030 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2014 | 93 | 0.030 |
Why?
| Serine Endopeptidases | 1 | 2014 | 57 | 0.030 |
Why?
| Bungarotoxins | 1 | 2012 | 7 | 0.030 |
Why?
| Intravitreal Injections | 1 | 2012 | 40 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 37 | 0.030 |
Why?
| Autophagy | 1 | 2014 | 202 | 0.030 |
Why?
| Receptors, Nicotinic | 1 | 2012 | 80 | 0.030 |
Why?
| Aged | 2 | 2022 | 10054 | 0.030 |
Why?
| Complement C9 | 1 | 2011 | 3 | 0.030 |
Why?
| Oxidation-Reduction | 1 | 2012 | 382 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2012 | 531 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 474 | 0.020 |
Why?
| Vision, Ocular | 1 | 2010 | 13 | 0.020 |
Why?
| Analysis of Variance | 1 | 2012 | 635 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2014 | 1476 | 0.020 |
Why?
| Transcriptome | 1 | 2012 | 346 | 0.020 |
Why?
| Gene Expression | 1 | 2012 | 664 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2009 | 289 | 0.020 |
Why?
| Models, Animal | 1 | 2009 | 255 | 0.020 |
Why?
| Immune System | 1 | 2004 | 49 | 0.020 |
Why?
| Immunoblotting | 1 | 2003 | 134 | 0.010 |
Why?
| Thromboplastin | 1 | 2003 | 8 | 0.010 |
Why?
| Gene Library | 1 | 2003 | 50 | 0.010 |
Why?
| Cell Adhesion | 1 | 2003 | 171 | 0.010 |
Why?
| Adenoviridae | 1 | 2003 | 58 | 0.010 |
Why?
| DNA, Complementary | 1 | 2003 | 145 | 0.010 |
Why?
| Retina | 1 | 2003 | 64 | 0.010 |
Why?
| Genetic Vectors | 1 | 2003 | 139 | 0.010 |
Why?
| Swine | 1 | 2003 | 431 | 0.010 |
Why?
| Protein Binding | 1 | 2003 | 736 | 0.010 |
Why?
| Liver | 1 | 2003 | 1225 | 0.010 |
Why?
| Middle Aged | 1 | 2003 | 13088 | 0.000 |
Why?
|
|
Bora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|